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Summary The role of cholecystokinin in dietary fat-promoted pancreatic carcinogenesis was investigated in
azaserine-treated rats, using lorglumide, a highly specific cholecystokinin-receptor antagonist. The animals
were killed 8 months after the start of treatment.
Cholecystokinin, but not dietary unsaturated fat, increased pancreatic weight. Rats treated with cholecys-
tokinin developed more acidophilic atypical acinar cell nodules, adenomas and adenocarcinomas than control
animals. Rats maintained on the high-fat diet developed significantly more adenomas and adenocarcinomas
than controls given a diet low in unsaturated fat. Lorglumide largely inhibited the enhancing effect of
cholecystokinin, but not of dietary fat, on pancreatic carcinogenesis indicating that it is unlikely that the
promoting effect of dietary unsaturated fat on pancreatic carcinogenesis is mediated via cholecystokinin.
Dietary fat has been implicated in the aetiology of various
human cancers, including pancreatic cancer. Epidemiology
has revealed a direct association between total fat consump-
tion and mortality of pancreatic cancer (Gordis & Gold,
1984; Lin & Kessler, 1981; MacMahon, 1982; Wynder et al.,
1973). Studies with azaserine-treated rats and with N-nitro-
sobis(2-oxopropyl)amine (BOP)-treated hamsters have dem-
onstrated that a diet high in unsaturated fat (maize oil)
promotes the development of pancreatic tumours (Roebuck
et al., 1981a, 1981b; Longnecker et al., 1986; Woutersen et
al., 1986, 1989; Birt et al., 1981). An increase in intra-
duodenal cholecystokinin (CCK) release is one of the pos-
tulated mechanisms by which a high-fat diet may be linked to
a high risk for pancreatic cancer. The cells producing the gut
hormone CCK are located in the small intestine and release
CCK into the circulation upon ingestion of food. CCK is
believed to be the most important hormonal regulator of
pancreatic enzyme secretion, and it is assumed that those
nutrients that stimulate pancreatic enzyme secretion do so by
stimulating CCK release. Douglas et al. (1988) have demon-
strated that unsaturated fat as well as protein administered
intragastrically to rats causes a rapid and significant rise in
plasma CCK exceeding the threshold for pancreatic stimula-
tion. This result suggests that CCK release induced by fat
and protein may play a role in the postprandial stimulation
of the pancreas in rats. In human volunteers ingestion of fat
also causes a rise in plasma CCK levels, especially with an
unsaturated fat such as maize oil (Beardshall et al., 1989).
Moreover, it has been demonstrated that lorglumide, a
highly specific CCK receptor antagonist (Makovec et al.,
1985, 1987), inhibits the promoting effect of CCK on panc-
reatic growth (Douglas et al., 1989c, 1990) and on the
development of putative preneoplastic acinar lesions induced
in rat pancreas by azaserine (Douglas et al., 1989a,c). Roe-
buck et al. (1987), however, did not find plasma CCK incre-
ments in rats maintained on a diet high in unsaturated fat,
which was due to an inadequate time of blood sampling in
combination with ad libitum feeding. We have demonstrated
that plasma CCK concentrations increase almost instantly
after ingestion of food and return to basal levels thereafter
(Douglas et al., 1988). This observation indicates that the
time lag between ingestion of food and collection of plasma
is highly critical with respect to the elucidation of the role of
CCK in diet-promoted pancreatic carcinogenesis. In the pres-
ent study the animals were gradually accustomed to eat only
one 4-h meal per day, either or not in combination with
pre-treatment with lorglumide, to allow us to manipulate the
food-induced release of CCK. Groups treated with CCK,




Two hundred and forty male weanling SPF Wistar rats
(WISW; Cpb) were obtained from F. Winkelmann (Versuch-
tiersucht, GmBh, Borchen, Germany). The animals were
housed in wire-mesh stainless steel cages, five animals per
cage, under standard laboratory conditions. The semi-
purified diets, either high or low in unsaturated fat (HF; 20%
maize oil or LF; 5% maize oil, respectively) were prepared
freshly each month in our institute and were stored at
- 20°C until use. The diets were composed of natural food
ingredients and contained equal amounts of minerals, trace
elements and vitamins per unit energy (Table I). The HF diet
contained also a high level of protein. Dietary protein
stimulates CCK release (Douglas et al., 1988), but has no
influence on pancreatic carcinogenesis (Roebuck et al.,
1981a).
Chemicals
Azaserine was purchased from the Calbiochem-Behring
Corp., La Jolla, CA, USA. Cholecystokinin-octapeptide
Table I Composition of the diets (% w/w)
Ingredients Highfat Lowfat




Wheat starch - 60.2
Pregelatinised starch 13.6 5.0
Cellulose 11.8 10.0
Jones-Foster minerals 5.3 4.5
KH2PO4 0.71 0.6
Vitamin ADEK 0.53 0.45
Vitamin B mixture 0.36 0.3
Choline chloride 0.47 0.4
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(CCK) was obtained from Cambridge Research Biochemical,
Cambridge, UK and Lorgiumide, a highly specific CCK-
receptor antagonist was kindly provided by Rotta Research
Laboratories, Milan, Italy.
Treatment
Azaserine was dissolved freshly in 0.9% NaCl solution. Each
rat was given three i.p. injections of 30 mg azaserine per kg
body weight at 19, 28 and 52 days of age. After the first
injection of azaserine the animals were maintained on the HF
diet for 4 months in order to enhance the yield of atypical
acinar cell nodules (AACN). During this period the animals
were gradually accustomed to eat for 4h per day (08.00
-12.00). This dietary regimen was continued for the rest of
the study. After the 4-month acclimatisation period the
animals were allocated to six different groups of 40 animals
each by a computerised randomisation procedure. Thereafter,
all animals in groups 1 to 4 were maintained on the LF diet
and received one of the following treatments (s.c. injection,
once daily, three consecutive days/week for 8 months): group
1, 0.9% NaCl (saline control); group 2, CCK in gelatin
(2.5jig kg-' body wt); group 3, lorglumide (12 mgkg' body
wt); group 4, CCK (2.5jigkg-' body wt) in combination
with lorglumide (12 mg kg-' body wt). The animals in group
5 and 6 were given the HF diet on three consecutive days per
week. On these days the animals in group 6 were treated with
lorglumide (12 mg kg-' body wt), while the animals in group
5 were injected with saline. The other 4 days of the week
these animals were maintained on the LF diet. Lorglumide
was dissolved in distilled water to a concentration of 0.4%
and adjusted to pH 9 with 0.1 M NaOH and subsequently
administered to the animals 30 min before injection of CCK
and 30 min before the animals received their feed. Drinking
water was available ad libitum. The dose of CCK used was
based on plasma concentration-time curves for CCK ob-
tained from a previously described 2-week study in rats and
hamsters (Douglas et al., 1989b). Subcutaneous injection of
2.5lgkg-' body wt CCK, dissolved in 16% hydrolysed
gelatin, resulted in plasma CCK levels that were only slightly
supraphysiological and comparable with those seen after
dietary administration of maize oil (Douglas et al., 1988).
Monitoring
Body weights were recorded weekly during the first 2 weeks,
every 2 weeks for 16 weeks thereafter and monthly for the
rest of the experimental period. The general condition and
behaviour of the animals were checked daily. A total of 31
animals, involving all groups, died before terminal autopsy.
The rats that died after 350 effective days (n = 4) in the study
have been included in the results. Twenty-seven rats (11%),
were excluded from the results because they died or were kill-
ed in extremis before day 350 of the study. Six of these
animals died or were killed owing to a bad condition caused
by the repeated injections (n = 3) or the malocclusion syn-
drome and subsequent anorexia (n = 3). Five animals died
presumably of renal failure, one rat of a bone tumour and
another one of a squamous cell carcinoma of the Zymbal's
gland. No cause of death could be established for 14 of the
animals because no autopsy was performed due to early
death (before day 85; n = 11) or to cannibalism (n = 3).
Analyses
Terminal autopsy was 371 days after the first injection of
azaserine. The animals were anaesthetised with ether, exsan-
guinated by cannulating the abdominal aorta, and examined
for gross pathological changes. The entire pancreas, liver and
all gross lesions were excised. The pancreas and liver of each
animal were weighed. All excised organs and all gross abnor-
malities suspected of being tumours were fixed in 10%
buffered formalin. The entire pancreata were processed for
microscopy by conventional methods, step-sectioned at 5tim,
stained with haematoxylin and eosin (H&E) and examined by
light microscopy. All pancreatic lesions were identified and
classified according to the criteria of Longnecker (1983) and
Rao et al. (1982). Atypical acinar cell nodules (AACN) were
recognised by phenotypic changes comprising an increased
rate of cell division, altered zymogen content of the cells,
changes in nuclear size, and loss of differentiation. Two
different populations of AACN have been characterised in
H&E-stained tissue sections by their markedly basophilic or
intense acidophilic cytoplasm. AACN have been defined as
those with a diameter smaller than 3 mm. Some lesions reach
diameters of 2-3 mm and a few reach diameters of 3-7 mm.
Lesions of the latter group that retained a high degree of
differentiation have been designated acinar cell adenomas.
Carcinoma in situ (CIS) is a lesion showing some degree of
anaplasia that suggests malignant growth potential but with-
out evidence oflocal invasion. Microcarcinomas was used for
a carcinoma in situ or an adenoma-like lesion exhibiting
anaplasia and focal invasion of the fibrous capsule or the
surrounding normal pancreatic tissue. Carcinomas show in-
vasion of adjacent tissues and may metastasise in periaortic
lymphnodes, liver and lungs. Quantitative determination of
the number of AACN per cm3 of pancreas was performed by
using a grid inside the ocular as described (Woutersen et al.,
1986; Scherer, 1981). The calculated volumetric data were
evaluated by analysis of variance. To minimise the SEM
some mathematical transformations were performed. The
total number of observed AACN per cm2, the mean transec-
tion area and the percentage of pancreas area occupied by
focus tissue were logarithmically transformed before stati-
stical evaluation. The calculated total number of AACN per
cm3 was prepared for statistical evaluation by taking the
square root. The mean diameters of AACN were not
mathematically transformed. The number of pancreatic
lesions was evaluated by a generalised linear regression model
(error is Poisson, link function is log). The incidence and
severity of pancreatic neoplasms were evaluated by a log-
linear model followed by chi-square tests for goodness of fit.
Results
Body and organ weights
Body weights remained similar for all groups. Both absolute
and relative liver weights of all treated animals were com-
parable with those of controls. The pancreata of animals
treated with CCK increased significantly in weight as com-
pared with controls (P<0.01).
Microscopy
Animals of the LF + lorglumide group and those of the HF
group irrespective of lorglumide treatment, showed no
differences in number and size of acidophilic AACN from
controls on a LF diet (Table II).
In rats treated with CCK we found an increase in number
(P<0.001), but not in mean diameter, of acidophilic lesions
resulting in an increase in area of pancreas occupied by
acidophilic tissue (P<0.001). Treatment with lorglumide
30min before CCK injection caused a significant inhibition
of the promoting effect of CCK on growth of acidophilic
AACN (P<0.001). The total number of acidophilic AACN
per cm3 in the CCK + lorglumide group was similar to that
in controls. The area of pancreas occupied by acidophilic
focus tissue had also decreased significantly (P<0.001) in
the group treated with CCK and lorglumide in comparison
with the group treated with CCK alone. Interestingly, the
effect of CCK on growth of acidophilic AACN was accom-
panied with a significant inhibitory effect on growth of
basophilic AACN as reflected in a decrease in total number
ofbasophilic nodules per cm3 (P<0.001), a decrease in mean
diameter (P<0.05) and in area of pancreas occupied by
basophilic focus tissue (P<0.01). Pre-treatment with lor-
glumide reduced significantly (P<0.05) the inhibitory effect
of CCK on growth of basophilic foci. The HF diet given for48 M.J. APPEL et al
3 days/wk, 4 h per day for 8 months caused a decrease
(P<0.05) in number of basophilic AACN in comparison
with animals maintained on the LF diet. Treatment of the
animals with lorglumide, 30 min before they received the HF
diet, resulted in a number of basophilic AACN similar to
that in controls. Treatment of rats with CCK increased the
number ofadenomas (P<0.01; Table III) and the number of
AACN with a diameter > 1.0mm (P<0.001). Lorglumide
inhibited this promoting effect of CCK on pancreatic car-
cinogenesis significantly. Furthermore, CCK alone enhanced
and lorglumide alone inhibited the development of microcar-
cinomas (Table III) and CCK also increased the total
number of carcinomas as compared to controls (P<0.05).
Lorglumide had only a slight inhibitory influence on this
effect of CCK. The HF diet caused an increase (P<0.05) in
number of pancreatic adenomas and adenocarcinomas. No
difference, however, was found in total number of car-
cinomas (comprising adenocarcinomas, CIS and microcar-
cinomas) between animals maintained on a HF diet and
controls. Pre-treatment with lorglumide did not influence the
promoting effects of the HF diet on pancreatic carcino-
genesis.
A shift towards malignant lesions was observed in the
CCK-treated group (Table IV). In this group 38% of the rats
developed a carcinoma versus 25% in the controls. This
increase is reflected in an increased incidence (P<0.05) of
animals with a microcarcinoma in the CCK-treated group. In
the group treated with lorglumide prior to CCK, the inci-
Table II Effects of CCK and a HF diet, either alone or in combination with Lorglumide, on development of
putative preneoplastic pancreatic foci induced in rats by azaserinet
Acidophilicfoci
Observed transection data offoci Calculated volumetric data offoci
No. Transection Mean
Treatment of Total area Total diameter Area as %
grouptt rats no. cm-2 (mm2 x 100) no. cm-3 (Atm) ofpancreas
LF 36 5.41 18.34 239.6 446.5 0.99
LF/CCK 37 22.22c 23.06b 716.6c 473.9 5.12c
LF/Lorglumide 35 5.73 20.99 253.5 457.0 1.20
LF/CCK/Lorglumide 35 9.22a,d 20.17 362.1d 462.9 1.86a,d
HF 34 4.15 19.39 163.6 455.3 0.80
HF/Lorglumide 36 5.60 20.68 201.9 463.8 1.16
Basophilicfoci
Observed transection data offoci Calculated volumetric data offoci
No. Transection Mean
Treatment of Total area Total diameter Area as %
grouptt rats no. cm-2 (mm2 x 100) no. cm-3 (Am) ofpancreas
LF 36 4.55 8.31 273.6 309.2 0.38
LF/CCK 37 2.37b 7.72 130.9e 292.3a 0.18b
LF/Lorglumide 35 4.40 7.34 288.7 292.5a 0.32
LF/CCK/Lorglumide 35 2.79a 7.70 161.3a 299.0 0.21a
HF 34 2.92 7.93 174.2a 307.9 0.23
HF/Lorglumide 36 3.70 8.33 222.0 304.6 0.31
tValues are means; ttLF, low fat; HF, high fat. Statistics: Analysis of variance followed by Student's t-test
(two-tailed); aP<0.05; bP<O.Ol; cP<0.001; as compared to LF controls; dP<O.OOl; as compared to the
LF/CCK-group.
Table III Effects of CCK and a HF diet, either alone or in combination with Lorglumide, on the number of pancreatic (pre)neoplastic lesions
induced in rats by azaserinet
Treatment Effective AACN Adenomas Micro- Adeno- Total
grouptt number ofrats (0> 1.0 mm) (0>3.0 mm) CIS carcinomas carcinomas carcinomas
LF 36 14 0 4 5 2 11
LF/CCK 37 go***a 7**,a 4 13*,b 4 21*.e
LF/Lorglumide 35 16 2 7 2* c 2 11
LF/CCK/Lorglumide 35 33**,a 1 6 4*,b,c 5 15*,e
HF 34 23 4*.a 2 1 5*,d 8
HF/Lorglumide 36 25 3 4 1*I 9*,d 14
tAll animals were fed for 4 h a day; ttLF, low fat; HF, high fat. Statistics: regression analysis (error is Poisson, link function is log); *P<0.05;
*P<0.01; ***P<0.001. aSignificantly different from the LF group; bTreatment with CCK caused an increase in number ofmicrocarcinomas as
compared toanimals kepton a LFdietand nottreated with CCK;cTreatment with Lorglumide caused a reduction innumberofmicrocarcinomas as
compared toanimals not treatedwith Lorglumide;dA HFdietcaused anincreasein numberofcarcinomasascompared toanimalskeptona LFdiet
for 7 days/week; eTreatment with CCK caused an increase in total number ofcarcinomas as compared to animals not treated with CCK.
Table IV Effects ofCCK and a HF diet, either alone or in combination with Lorglumide, on the incidence ofpancreatic (pre)neoplastic lesions
induced in rats by azaserinet
Treatment Effective Tumour- Carcinoma- AACN Adenomas Micro- Adeno
grouptt number ofrats bearing rats (%)bearing rats (%) (0>1mm) (0>3 mm) CIS carcinomas carcinomas
LF 36 9 (25) 9 (25) 8 0 4 3 2
LF/CCK 37 18 (49) 14 (38) 12 4 4 6a 4
LF/Lorglumide 35 9 (26) 7 (20) 6 2 4 1 2
LF/CCK/Lorglumide 35 10 (29) 10 (29) 6 0 4 2 4
HF 34 10 (29) 7 (21) 8 3 1 1 5
HF/Lorglumide 36 14 (39) 13 (36) 9 1 3 1 ga
tAll animals were fed for 4 h a day; ttLF, low fat; HF, high fat. Statistics: Log-linear model followed by chi-square tests for goodness of fit;
ap< 0.05, as compared to LF controls.CCK AND DIETARY FAT-PROMOTED CARCINOGENESIS 49
dence of pancreatic tumours was similar to that in controls.
The group maintained on a HF diet and pre-treated with
lorglumide showed a higher incidence (P<0.05) of adenocar-
cinomas than controls. Since lorglumide alone did not result
in a rise in incidence, the latter effect is considered to be
attributable to the HF diet.
Discussion
The present study was conducted to investigate whether
dietary fat-promoted pancreatic carcinogenesis in rats is
mediated via an increased duodenal release of CCK. It has
been demonstrated that lorglumide, a specific CCK-receptor
antagonist, remains in its active form for about 4 to 6 h
(Makovec et al., 1985). To be able to modulate the CCK
release induced by the ingestion of food we chose a dietary
regimen consisting of one 4-h meal per day. To establish
whether the enhancing effect of a HF diet on pancreatic
carcinogenesis is indeed mediated via CCK, we injected lor-
glumide 30min before the animals received their respective
diets to occupy the CCK receptors before CCK is released
from the intestines. A disadvantage of the 4-h meal regimen
used was a significant decrease in body weight gain as com-
pared to a parallel study with azaserine-treated rats fed ad
libitum (average body weight in the present study after 12
months was 400g versus 467 g in the parallel study). The
decrease in body weight gain might be a confounding factor
in the present study, since it is well known that an energy-
restricted diet (10%) has a significant inhibitory effect on
azaserine-induced pancreatic carcinogenesis in rats (Roebuck
et al., 1981a). Indeed, the tumour incidences in the present
study appeared to be consistently lower than in the parallel
study in which the animals were fed ad libitum.
The present results obtained with CCK are in agreement
with those of previous studies (Douglas et al., 1989a; 1989c;
1990). CCK administration enhances pancreatic growth as
well as pancreatic carcinogenesis in azaserine-treated rats in
spite of the restricted feeding regimen. Also of great interest
is the observation that, whereas CCK enhances growth of
acidophilic AACN, it inhibits the growth of basophilic foci.
This effect of CCK is slightly inhibited by lorglumide. In a
previous study we have observed the same phenomenon with
the synthetic trypsin inhibitor Camostate (Douglas et al.,
1989c). These results support our conclusion that, besides
acidophilic foci, also basophilic foci may be responsive to
modulators of carcinogenesis and may play a role in the
development of pancreatic cancer in azaserine-treated rats
(Woutersen et al., 1986, 1988). It is, therefore, of paramount
importance not to neglect these putative preneoplastic lesions
in studies of pancreatic carcinogenesis. Moreover, the
significance of these observations needs further elucidation.
Even under the circumstances of a single 4-h meal the HF
diet enhances the development ofpancreatic acinar adenocar-
cinomas, albeit less pronounced than in a previous study in
which the rats were fed ad libitum (Woutersen et al., 1989).
Lorglumide did not influence the promoting effects of the HF
diet on pancreatic carcinogenesis. This observation is not in
agreement with that of Smith et al. (1990), who reported that
L 364,718, a potent CCK-receptor antagonist, decreased the
volume and weight of a xenografted human pancreatic
tumour cell line in athymic mice. Moreover, they also found
a reduction in dietary fat-promoted growth of these xeno-
grafts by L 364,718. These apparently contradictory findings
are most probably due to differences in tumour types induced
by azaserine in rats (almost exclusively acinar adenocar-
cinomas) and those occurring in man (duct cell adenocar-
cinomas). Syrian golden hamsters treated with N-nitrosobis
(2-oxopropyl)amine (BOP) develop ductular tumours which
resemble those occurring in man. In the BOP-hamster model
CCK has been found to have no effect or an inhibitory effect
on pancreatic carcinogenesis (Pour et al., 1988; Meijers et al.,
1990).
In the present study, CCK enhanced multiplicity and
incidence of pancreatic tumours. The HF diet also promoted
development ofpancreatic tumours, but in a less pronounced
manner. Lorglumide largely inhibited the CCK effect on
pancreatic tumour development, but did not influence the
effect of the HF diet. In fact, the number and incidence of
adenocarcinomas was highest in the HF + lorglumide group.
The latter observation may indicate a possible unknown
interaction between HF and lorglumide. However, the lack of
statistical evidence for such an interaction and the slight
inhibitory effect observed with lorglumide alone, suggest that
the promoting effect of HF + lorglumide is attributable to
HF. The number of rats bearing a microcarcinoma was
significantly higher in animals treated with CCK than in the
other groups. Pre-treatment with lorglumide completely inhi-
bited this effect. Moreover, CCK enhanced pancreatic
weight, whereas the HF diet did not. These results indicate
that both CCK and a HF diet enhance pancreatic car-
cinogenesis in azaserine-treated rats. The mechanism of these
two promoters of pancreatic carcinogenesis, however, seems
to be different. Lorglumide largely inhibited the enhancing
effect of CCK, but not of dietary fat, indicating that it is
unlikely that the promoting effect of dietary unsaturated fat
on pancreatic carcinogenesis is mediated via CCK. The
mechanism by which dietary (un)saturated fat promotes car-
cinogenesis is still largely unknown. Several mechanisms have
been postulated by which a diet high in (un)saturated fat
may be linked to a high risk for some cancers (Karmali,
1988). A hypothetical explanation for dietary fat-promoted
tumour growth involves the acceleration of linoleic acid-
derived arachidonic acid metabolism resulting in enhanced
production of eicosanoids such as prostaglandins, thrombox-
anes and leukotrienes (Karmali, 1983). Investigations are
currently in progress to find out whether prostaglandins play
a role in dietary fat-promoted pancreatic carcinogenesis using
both the azaserine-rat and the BOP-hamster model.
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